Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
PT Bio Farma clinical trials
Part of PT Danantara Asset Management (Persero).
The registry lists 50 studies whose lead sponsor is PT Bio Farma or one of 1 company grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 2, 2026.
Keep track of what changes. Save the PT Bio Farma studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesWhere
- Indonesia
- 48
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to PT Bio Farma.
- PT Bio Farma46 studiesSame company
Something wrong?
- PT. Kimia Farma (Persero) Tbk4 studies →Acquired — became part of PT Bio Farma, Jan 2020 · source ↗
Something wrong?
Focus areas
Conditions PT Bio Farma leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 50.
- Study Interchangeability Hep-B Vaccine Administered at Birth DoseNot yet recruitingNCT07854847Phase 3
- Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in ChildrenNot yet recruitingNCT07824310Phase 3
- A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy PopulationsNot yet recruitingNCT07647107Phase 1
- Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)Not yet recruitingNCT05482295Phase 3
- Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCVNot yet recruitingNCT06921460
- Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian InfantsNot yet recruitingNCT06690515Phase 1/2
- Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS PatientsCompletedNCT06114641Phase 4
- Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)WithdrawnNCT05482282Phase 3
- Homologous Booster Study of COVID-19 Protein Subunit Recombinant VaccineCompletedNCT05933278Phase 2
- Booster Study of COVID-19 Protein Subunit Recombinant VaccineCompletedNCT05525208Phase 2
- Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in IndonesianCompletedNCT04741828Phase 2/3
- Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy ChildrenCompletedNCT05546502Phase 3
- Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of AgeCompletedNCT05727215Phase 2
- Post Authorization Safety Profile of Booster IndoVac COVID-19 VaccinationCompletedNCT06690502
- Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in NeonatesCompletedNCT04185545Phase 3
- Immuno-bridging Study of COVID-19 Protein Subunit Recombinant VaccineCompletedNCT05433285Phase 3
- Post Authorization Safety Study Moderna COVID-19 Primary VaccineCompletedNCT06006858
- Post Marketing Surveillance of Diphtheria Antitoxin (DAT)CompletedNCT06053853Phase 4
- Bioequivalence Study of Furosemide 40 mg Tablet in 24 Indonesian Healthy VolunteersCompletedNCT04982874Not applicable
Sponsor listed in the registry: PT. Kimia Farma (Persero) Tbk · First submitted after PT. Kimia Farma (Persero) Tbk became part of PT Bio Farma
- Detection of High-Risk HPV in Urine and Cervical Swab Specimen Using HPV Diagnostic Kit (Bio Farma)CompletedNCT06111911Not applicable
- Preventive Care System Application Effectiveness Study on the Treatment of Diabetic Patients in BandungStatus unknownNCT05657769Not applicable
- Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant VaccineCompletedNCT05313035Phase 2/3
- Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018CompletedNCT05228613Phase 1
- Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy SubjectCompletedNCT04988646Not applicable
Sponsor listed in the registry: PT. Kimia Farma (Persero) Tbk · First submitted after PT. Kimia Farma (Persero) Tbk became part of PT Bio Farma
- Safety and Tuberculin Conversion Following BCG VaccinationCompletedNCT05124340Phase 2
- Protectivity and Safety Following Recombinant Hepatitis B VaccineCompletedNCT03919578Phase 2/3
- The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated VaccineStatus unknownNCT05126550
Sponsor listed in the registry: PT. Kimia Farma (Persero) Tbk · First submitted after PT. Kimia Farma (Persero) Tbk became part of PT Bio Farma
- Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)Status unknownNCT05172193Phase 2
Sponsor listed in the registry: PT. Kimia Farma (Persero) Tbk · First submitted after PT. Kimia Farma (Persero) Tbk became part of PT Bio Farma
- Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant VaccineCompletedNCT05067894Phase 1
- Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & ChildrenCompletedNCT04188223Phase 1
- Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in IndonesiaCompletedNCT05037227
- Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis BCompletedNCT04071379Phase 3
- Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated VaccineCompletedNCT04508075Phase 3
- Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)CompletedNCT04051268Phase 3
- Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and InfantsCompletedNCT03460405Phase 2
- Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)CompletedNCT04183114Phase 2/3
- Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and ChildrenCompletedNCT03680417Phase 4
- Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & NeonatesCompletedNCT03462108Phase 1
- Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian PopulationCompletedNCT03336593Phase 2
- Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)CompletedNCT03109600Phase 1
- Safety Profile Following Td Vaccination in Indonesian Pregnant WomanCompletedNCT03383653
- Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPVCompletedNCT03310073Phase 4
- Safety Profile Following Pentabio Vaccination in Indonesian InfantsCompletedNCT02093286
- Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)CompletedNCT02093260Phase 2/3
- Antibody Persistence, Immune Response and Safety After Doses of Pentabio VaccineCompletedNCT02095314Phase 2/3
- Evaluation on Immunogenicity and Safety Profile of Trivalent OPV (tOPV Bio Farma)CompletedNCT02093273Phase 2
- Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center TrialCompletedNCT01986335Phase 3
- Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)VaccineCompletedNCT01986322Phase 2
- The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)CompletedNCT01977196Phase 1
- Safety of Hib Vaccine (Bio Farma)CompletedNCT01977170Phase 1